T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
NCT ID: NCT05435014
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
90 participants
INTERVENTIONAL
2022-09-13
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase I part:
12 evaluable subjects will be enrolled sequentially in Phase I part. The first 3 subjects will receive TAE treatment (whether or not they are contraindicated to Doxorubicin) and the following 3 subjects (4th to 6th subjects) will receive TACE treatment. The remaining subjects may receive TAE or TACE treatment. Subjects will be enrolled sequentially in Phase I. For the first six subjects in Phase I, after the subject completes TAE or TACE treatment and is followed for 2 weeks, safety and tolerability data during this period will be reviewed by the safety review committee (SRC); only approved by the SRC, the next subject may start the TAE or TACE treatment. For the 7th to 12th subjects in Phase I, after the subject completes TAE or TACE treatment and is followed until discharge from hospitalization, safety and tolerability data during this period will be reviewed by the safety review committee (SRC); only approved by the SRC, the next subject may start the TAE or TACE treatment. After data for all 12 evaluable subjects are reviewed by SRC and approval is given by the SRC, the study may proceed to Phase II part.
Phase II part:
70 evaluable subjects will be randomized in a 1:1 ratio to receive TAE/TACE treatment by T-ACE Oil or Lipiodol for safety and efficacy evaluation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T-ACE Oil
TAE/TACE treatment was performed with T-ACE Oil.
T-ACE Oil
TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Lipiodol
TAE/TACE treatment was performed with Lipiodol.
Lipiodol
TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T-ACE Oil
TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Lipiodol
TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients diagnosed of HCC (Meet at least ONE of the following criteria):
A. Diagnosed via tumor biopsy by pathologists and confirmed by on-service physician.
B. High risk patients (viral hepatitis B or C or cirrhotic) with typical liver cancer image appeared on MRI or CT scan.
3. In very early stage to intermediate stage by BCLC staging (2018 AASLD), HCC tumor numbers ≦ 10, HCC tumor size ≦ 15 centimeters (determined by CT, MRI or ultrasound), with liver function at Child-Pugh score\[1\] ≦ 8.
4. Disease can be treated by trans-arterial chemoembolization, and can be evaluated by Magnetic resonance imaging (MRI), or computed tomography (CT).
5. Patients who only require a single TAE/TACE treatment to treat all HCC tumors at once.
6. Target HCC tumors should have at least 1 tumor that is larger than 1 cm in diameter (determined by CT, MRI or ultrasound) and non-treated before.
7. May have received local therapy such as TAE, TACE, radiofrequency ablation (RFA) or surgery and remain eligible for study provided the prior therapy was within the following timeframes and the subject has fully recovered from prior therapy:
A. TAE/TACE: more than 8 weeks since completion of prior therapy B. RFA: After PI confirm subject is fully recovered from prior therapy based on screening visit physical examination and liver function laboratory tests results.
C. Surgery: After PI confirm subject is fully recovered from prior therapy based on screening visit physical examination and liver function laboratory tests results.
8. Patients able to understand, willing to accept and cooperate with all clinical trial practices.
9. Willing to sign a written informed consent form.
Exclusion Criteria
2. Eligible for curative surgery or transplant as judged by PI.
3. Evidences of decompensation (Meet at least ONE of the following criteria):
* Total Bilirubin \> 2 mg/dL
* INR \> 1.7
* Child-Pugh score \> 8
* refractory ascites
* active bleeding
* hepatic encephalopathy
* severe infection
4. Any of the following findings (but not limit to):
* Heart failure (NYHA Class III or IV), COPD (Stage III or IV).
* A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>480 milliseconds (ms) (CTCAE grade 1) using Fridericia's QT correction formula.
* A history of risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or use of concomitant medications that prolong the QT/QTc interval (e.g., class Ia, Ic or III antiarrhythmic drugs, tricyclic antidepressants or phenothiazines)
* Bronchial asthma that may increase the risk associated with study participation, or may interfere with compliance of the protocol as judged by the PI.
* Renal dysfunction (eGFR \< 50 ml/min/1.73m2 and/or creatinine \> 1.5x ULN), or patients is planned to accept any renal replacement therapy during treatment visits.
* Diagnosed with hyperthyroidism or receiving treatment for hyperthyroidism. Has unstable thyroid function as judged by the PI (e.g. TSH \> 5.0 mIU/L).
* Traumatic injuries, clinically significant hemorrhage/bleeding, or clinically significant gastrointestinal bleeding within 8 weeks.
* Major cardiovascular disease, including stroke and transient ischemic attack (TIA).
* Known homocystinuria.
5. Any of the following laboratory findings:
* Absolute Neutrophil Count \< 1000/μL
* Platelets \< 50,000/μL
* Hgb \< 8.5 g/dL
* AST \> 5x ULN
* ALT \> 5x ULN
6. Performance status Eastern Cooperative Oncology Group (ECOG) of 2 or more.
7. Patients whose blood vessel are too difficult to perform TACE procedure as judged by PI.
8. TACE procedure would be performed in areas of the liver where bile ducts are dilated as judged by PI.
9. Prominent Hepatic arteriovenous (AV) shunt, as judged by PI.
10. Non-targeted area may be endangered during TACE procedure, as judged by PI.
11. Patients, who have ever accepted TACE therapy, and cannot gain extra benefits from further embolization treatment.
12. Number of HCC tumors more than 10.
13. Allergy or contraindication to iodine, Lipiodol, allowed contrast agents, allowed Gelfoam suppositories or allowed artery hemostats.
14. Pregnant females or lactating females.
15. Male or female subjects with fertility who are unwilling to perform highly effective contraception method.
16. Subjects who, in the opinion of the investigator, are not suitable to participate in the trial for whatever reason.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
T-ACE Medical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Po-Chin Liang, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Xi-Zhang Lin, MD
Role: STUDY_CHAIR
T-ACE Medical Co., Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaohsiung Veterans General Hospital
Kaohsiung City, , Taiwan
Tungs' Taichung Metroharbor Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wei-Lun Tsai, MD
Role: primary
Yu-Ting Huang, BS
Role: backup
Jen-I Hwang, MS, MD
Role: primary
Yu-Chen Chen, MS, BS
Role: backup
Hung-Chih Chiu, MS, MD
Role: primary
Shih-Fen Chang, RN
Role: backup
Po-Chin Liang, PhD, MD
Role: primary
Yun-Ping Lin, RN
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, Nakashima Y, Notsumata K, Toya D, Tanaka N, Mitsui T, Matsui O. Chemoembolization for the treatment of large hepatocellular carcinoma. J Vasc Interv Radiol. 2010 Aug;21(8):1226-34. doi: 10.1016/j.jvir.2010.04.015. Epub 2010 Jul 3.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7.
Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, Tacher V, Duran R, Geschwind JF. Three-dimensional evaluation of lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol. 2014 Mar;21(3):393-9. doi: 10.1016/j.acra.2013.11.006.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TACE-OHEP-001
Identifier Type: -
Identifier Source: org_study_id